The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

Weight-loss drugs and prescription medications for ADHD are among the latest items being offered for sale by dealers, an investigation found ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

More than 15.5 million Americans have tried weight loss injectables, but risks are rising with the proliferation of ...

Clinical neuroscientist Joe Schacht offered an overview of the research on weight-loss drugs for alcoholism, other potential ...

The Food and Drug Administration announced Friday it had officially declared an end to the nationwide shortage of Ozempic and Wegovy, medications used for diabetes and weight loss. The agency first ...

Novo Nordisk extended a four-day winning streak on Friday, adding 5.18 percent to close at $88.08 apiece as investors cheered ...

Utah’s Attorney General Derek Brown signed onto a letter along with attorneys general from 37 other states to ask the Food and Drug Administration to enforce the safety of weight loss drugs.

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...